Carl Zeiss Meditec AGXSWX:AFX 70 EV-to-EBITDA is 13.97 as of Jul. 13, 2026, which is 46% below its 10-year median of 25.68. GuruFocus rates XSWX:AFX with a GF Score™ of 70/100 and a GF Value™ of CHF314.66 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 513 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks worse than 51.07% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Carl Zeiss Meditec AG's enterprise value is CHF2,576 Mil.
Carl Zeiss Meditec AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF184 Mil. Therefore, Carl Zeiss Meditec AG's EV-to-EBITDA for today is 13.97.
The historical rank and industry rank for Carl Zeiss Meditec AG's EV-to-EBITDA or its related term are showing as below:
XSWX:AFX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.83 Med: 25.68 Max: 57.8
Current: 14.29
During the past 13 years, the highest EV-to-EBITDA of Carl Zeiss Meditec AG was 57.80. The lowest was 9.83. And the median was 25.68.
XSWX:AFX's EV-to-EBITDA is ranked worse than 51.07% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.17
vs XSWX:AFX: 14.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Carl Zeiss Meditec AG (XSWX:AFX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Carl Zeiss Meditec AG's PE Ratio (TTM) for today is calculated as:
Carl Zeiss Meditec AG's share price for today is CHF26.30.
Carl Zeiss Meditec AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.292.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Carl Zeiss Meditec AG EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Carl Zeiss Meditec AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:AFX vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's EV-to-EBITDA falls into.
Carl Zeiss Meditec AG's current Enterprise Value is CHF2,576 Mil.
Carl Zeiss Meditec AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF184 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carl Zeiss Meditec AG (XSWX:AFX) has a EV-to-EBITDA of 13.97 as of Jul. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Carl Zeiss Meditec AG. This is 46% below median its historical median of 25.68. Over the past decade, Carl Zeiss Meditec AG's EV-to-EBITDA has ranged from 9.83 to 57.80. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #262 out of 513 companies in the Medical Devices & Instruments industry, placing it in the top 51.1%.
Is Carl Zeiss Meditec AG's EV-to-EBITDA too high?
Carl Zeiss Meditec AG's current EV-to-EBITDA of 13.97 is 46% below median its 10-year median of 25.68. Over the past 10 years, this metric has ranged from a low of 9.83 to a high of 57.80. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.17. Carl Zeiss Meditec AG's value of 13.97 is 1.4% below this industry median. Based on the distribution chart, Carl Zeiss Meditec AG ranks #262 out of 513 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Carl Zeiss Meditec AG has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #262 out of 513 companies for EV-to-EBITDA. This places Carl Zeiss Meditec AG in the lower half of its industry. The industry median EV-to-EBITDA is 14.17. Carl Zeiss Meditec AG's value of 13.97 is 1.4% below this benchmark. Historically, Carl Zeiss Meditec AG's own EV-to-EBITDA has ranged from 9.83 to 57.80 over the past decade. While the company's 10-year median is 25.68 vs. the industry median of 14.17, Carl Zeiss Meditec AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.17, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carl Zeiss Meditec AG's current EV-to-EBITDA of 13.97 is 1.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Carl Zeiss Meditec AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current EV-to-EBITDA is 13.97, which is 46% below median its own 10-year median of 25.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF314.66, compared to a current price of CHF26.30 — trading 91.6% below its estimated fair value. The current EV-to-EBITDA is 13.97, which is 46% below median its 10-year median of 25.68 and 1.4% below the Medical Devices & Instruments industry median of 14.17. Carl Zeiss Meditec AG's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current EV-to-EBITDA is 13.97 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of CHF26.30 is trading 91.6% below its estimated GF Value™ of CHF314.66.
GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.
Key valuation signals for XSWX:AFX:
EV-to-EBITDA: 13.97 (46% below median its 10-year median of 25.68)
GF Value™: CHF314.66 vs. price of CHF26.30 (91.6% below fair value)
Industry Position: 1.4% below the Medical Devices & Instruments median (#262 of 513)
No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
70GF Score
Get the complete analysis for XSWX:AFX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:AFX has been successfully added to your 
